Apollo Therapeutics bags $226.5 million to develop medicines based on uni research

6 September 2023

Cambridge, US-based Apollo Therapeutics today announces the close of $226.5 million in a Series C financing led by lead investor Patient Square Capital.

Founded in 2015 by the tech offices of Imperial, Cambridge and UCL, Apollo is a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach.

Participating in the financing are multiple new investors including M&G plc and two of the largest US public pension plans, along with existing investor Rock Springs Capital. The financing significantly adds to the $195 million previously raised by the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK